Drug
[68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.
[68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G. is a pharmaceutical drug with 3 clinical trials. Currently 3 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
3(100%)
Phase Distribution
Ph phase_1
2
67%
Ph early_phase_1
1
33%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 1Safety & dosage
2(66.7%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
3
all time
Status Distribution
Active(3)
Detailed Status
Recruiting3
Development Timeline
Analytics
Development Status
Total Trials
3
Active
3
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Early Phase 11 (33.3%)
Phase 12 (66.7%)
Trials by Status
recruiting3100%
Recent Activity
3 active trials
Showing 3 of 3
recruitingearly_phase_1
First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer
NCT04665947
recruitingphase_1
Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas
NCT06389123
recruitingphase_1
Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6
NCT06228482
Clinical Trials (3)
Showing 3 of 3 trials
NCT04665947Early Phase 1
First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer
NCT06389123Phase 1
Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas
NCT06228482Phase 1
Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3